Shouyao Holdings (Beijing) Valuation

Is 688197 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688197 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 688197's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 688197's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688197?

Key metric: As 688197 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 688197. This is calculated by dividing 688197's market cap by their current book value.
What is 688197's PB Ratio?
PB Ratio	5.4x
Book	CN¥860.97m
Market Cap	CN¥4.62b

688197 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	944.2x
Enterprise Value/EBITDA	-16x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 688197's PB Ratio compare to its peers?

The above table shows the PB ratio for 688197 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	2.6x
002793 Luoxin Pharmaceuticals Group Stock	2.1x	n/a	CN¥4.4b
603669 Lionco Pharmaceutical GroupLtd	4.8x	n/a	CN¥4.1b
300158 Shanxi Zhendong PharmaceuticalLtd	1x	n/a	CN¥4.9b
300006 Chongqing Lummy Pharmaceutical	2.5x	n/a	CN¥5.1b
688197 Shouyao Holdings (Beijing)	5.4x	35.4%	CN¥4.6b

Price-To-Book vs Peers: 688197 is expensive based on its Price-To-Book Ratio (5.4x) compared to the peer average (2.6x).

Price to Book Ratio vs Industry

How does 688197's PB Ratio compare vs other companies in the CN Pharmaceuticals Industry?

1 Company	Price / Book	Estimated Growth	Market Cap
002435 Changjiang Runfa Health Industry	0.1x	n/a	US$63.75m

No more companies available in this PB range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 688197 is expensive based on its Price-To-Book Ratio (5.4x) compared to the CN Pharmaceuticals industry average (2.1x).

Price to Book Ratio vs Fair Ratio

What is 688197's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688197 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	5.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 688197's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

-1.4%

-24.4%

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.05

3.7%

7.9%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

-1.8%

13.3%